Correction to: Journal of Medical Toxicology
This article contains a couple typographical errors in the table and in the formatting of references. The authors and the journal apologize for those errors and respectfully include a corrected table and corrected reference list here.
References
Dart RC, Goldfrank LR, Chyka PA, Lotzer D, Woolf AD, McNally J, Snodgrass WR, Olson KR, Scharman E, Geller RJ, Spyker D, Kraft M, Lipsy R. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36: 126-132.
Kesselheim AS, Avorn Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;318:858-71.
FDA. Frequently asked questions about patents and exclusivity. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed October 21, 2016.
Kesselheim AS. Using market exclusivity incentives to promote pharmaceutical innovation. N Eng J Med 2010;363:1855-62.
Divino V, DeKoven M, Kleinrock M. Orphan drug expenditures in the United States: a historical and prospective analysis, 2007-18. Health Aff 2016;35:1588-94.
Tufts Center for the Study of Drug Development. Costs to develop and win marketing approval for a new drug is $2.6 billion. http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study. Accessed October 21, 2016.
Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States and what are the solutions? Mayo Clin Proc 2015;90:500-4.
Reference for prices of new drugs are higher in the US Hirschler B. Exclusive—transatlantic divide: how US pays three times more for drugs. Reuters. http://www.reuters.com/article/us-pharmaceuticals-usa-comparison-idUSKCN0S61KU20151012. Published October 12, 2015. Accessed July 26, 2017.
Kanavos P, Ferraio A, Vandoros S, Anderson GF. Higher U.S. branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Heath Aff 201;32:753-61.
National Institute for Health Care and Excellence (NICE). https://www.nice.org.uk. Accessed October 26, 2016.
Qualifying for pediatric exclusivity under Section 505A of the Federal Food, Drug, and Cosmetic Act: frequently asked questions on pediatric exclusivity (505A), The Pediatric "Rule," and their interaction. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm077915.htm. Accessed October 21, 2016.
BTG settles CroFab patent litigation with Bioclon and RDT. https://www.thepharmaletter.com/article/btg-settles-crofab-patent-litigation-with-bioclon-and-rdt. Accessed August 26, 2017.
Uhl K, Peters JR, Flanagan K. High-cost generic drugs-implications for patients and policymakers. N Engl J Med 2015;372:685-6.
O’Brien E. Why drug prices remain insanely high and 6 things you can do to save. http://www.marketwatch.com/story/six-tips-for-fighting-rising-prescription-drug-costs-2015-09-15. Accessed July 26, 2017
Red Book Online® [database online]. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed January 23, 2016.
Heindel GA, Trella JD, Osterhoudt KC. Rising cost of antidotes in the US: cost comparison from 2010 to 2015. Clin Toxicol 2017; 55: 360-363.
NPR. Price soars for key weapon against heroin overdoses. http://www.npr.org/sections/health-shots/2015/09/10/439219409/naloxone-price-soars-key-weapon-against-heroin-overdoses. Accessed October 21, 2016.
STAT. Doctors have toxic reaction to Valent pricing for a lead poisoning drug. https://www.statnews.com/pharmalot/2016/10/11/valeant-drug-prices-lead-poisoning/. Accessed October 21, 2016.
The Washington Post. This $153,000 rattlesnake bite is everything wrong with American healthcare. https://www.washingtonpost.com/news/wonk/wp/2015/07/20/this-153000-rattlesnake-bite-is-everything-wrong-with-american-health-care/. Accessed October 26, 2016.
Red Book Online® [database online]. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed November 15, 2012.
Red Book Online® [database online]. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed March 8, 2016.
Red Book Online® [database online]. Greenwood Village, Colorado: Thomson Reuters (Healthcare) Inc. Updated periodically. Accessed June 20, 2017.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s13181-017-0639-z
Rights and permissions
About this article
Cite this article
Mazer-Amirshahi, M., Stolbach, A. & Nelson, L.S. Correction to: ACMT Position Statement: Addressing the Rising Cost of Prescription Antidotes. J. Med. Toxicol. 14, 174–176 (2018). https://doi.org/10.1007/s13181-018-0652-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-018-0652-x